PL3691692T3 - Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania - Google Patents

Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania

Info

Publication number: PL3691692T3
Authority: PL; Poland
Prior art keywords: methods; drug conjugates; antibody drug; activatable antibody; activatable
Prior art date: 2017-10-14

Application number

PL18797311T

Other languages

English (en)

Inventor

Shweta SINGH

Jennifer Hope RICHARDSON

Laura Patterson SERWER

Jonathan Alexander Terrett

Susan E. Morgan-Lappe

Tracy HENRIQUES

Sherry L. RALSTON

Marvin Robert Leanna

Ilaria BADAGNANI

Sahana Bose

Original Assignee

Abbvie Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-14

Filing date

2018-10-12

Publication date

2021-07-19

2018-10-12 Application filed by Abbvie Inc. filed Critical Abbvie Inc.

2021-07-19 Publication of PL3691692T3 publication Critical patent/PL3691692T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL18797311T 2017-10-14 2018-10-12 Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania PL3691692T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762572467P	2017-10-14	2017-10-14
PCT/US2018/055733 WO2019075417A1 (en)	2017-10-14	2018-10-12	CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE
EP18797311.0A EP3691692B8 (en)	2017-10-14	2018-10-12	Anti-cd71 activatable antibody drug conjugates and methods of use thereof

Publications (1)

Publication Number	Publication Date
PL3691692T3 true PL3691692T3 (pl)	2021-07-19

Family

ID=64110112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18797311T PL3691692T3 (pl)	2017-10-14	2018-10-12	Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania

Country Status (36)

Country	Link
US (3)	US20190111150A1 (pl)
EP (2)	EP3691692B8 (pl)
JP (2)	JP7374891B2 (pl)
KR (4)	KR102385495B1 (pl)
CN (1)	CN111278467B (pl)
AR (1)	AR115178A1 (pl)
AU (1)	AU2018346969A1 (pl)
BR (1)	BR112020007302B1 (pl)
CA (1)	CA3077730A1 (pl)
CL (1)	CL2020000977A1 (pl)
CO (1)	CO2020005685A2 (pl)
CR (1)	CR20200206A (pl)
CY (1)	CY1123968T1 (pl)
DK (1)	DK3691692T3 (pl)
DO (1)	DOP2023000150A (pl)
EC (1)	ECSP20025198A (pl)
ES (1)	ES2864013T3 (pl)
HR (1)	HRP20210436T8 (pl)
HU (1)	HUE054037T2 (pl)
IL (1)	IL273586A (pl)
LT (1)	LT3691692T (pl)
MA (1)	MA50752B1 (pl)
MD (1)	MD3691692T2 (pl)
MX (1)	MX2020003723A (pl)
PE (1)	PE20210125A1 (pl)
PH (1)	PH12020550417A1 (pl)
PL (1)	PL3691692T3 (pl)
PT (1)	PT3691692T (pl)
RS (1)	RS61596B1 (pl)
RU (2)	RU2771292C2 (pl)
SG (1)	SG11202003378WA (pl)
SI (1)	SI3691692T1 (pl)
SM (1)	SMT202100184T1 (pl)
TW (2)	TW202330039A (pl)
UY (1)	UY37931A (pl)
WO (1)	WO2019075417A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130116404A1 (en)	2011-11-08	2013-05-09	Case Western Reserve University	Targeted non-invasive imaging probes of egfr expressing cells
BR112017023862A2 (pt)	2015-05-04	2018-07-17	Cytomx Therapeutics Inc	anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
FI3635009T3 (fi)	2017-06-07	2026-04-07	Regeneron Pharma	Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
RU2771292C2 (ru) *	2017-10-14	2022-04-29	Эббви Инк.	Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения
JP7779653B2 (ja)	2018-02-07	2025-12-03	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	治療用タンパク質送達のための方法および組成物
WO2019183633A1 (en)	2018-03-23	2019-09-26	Case Western Reserve Univeristy	Psma targeted conjugate compounds and uses thereof
EP3793591A1 (en)	2018-05-17	2021-03-24	Regeneron Pharmaceuticals, Inc.	Anti-cd63 antibodies, conjugates, and uses thereof
KR20220164773A (ko) *	2020-04-08	2022-12-13	앨리어다 테라퓨틱스, 인코포레이티드	혈액-뇌 장벽 전달용 조성물 및 방법
BR112022019841A2 (pt) *	2020-04-09	2022-12-06	Cytomx Therapeutics Inc	Composições contendo anticorpos ativáveis
WO2022020108A1 (en) *	2020-07-23	2022-01-27	Dyne Therapeutics, Inc.	Muscle-targeting complexes and uses thereof
CA3237590A1 (en)	2021-11-09	2023-05-08	James Basilion	Psma targeted conjugate compounds and uses thereof
IL318625A (en) *	2022-07-29	2025-03-01	Regeneron Pharma	Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
AU2024299328A1 (en)	2023-07-21	2026-01-22	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025133132A1 (en) *	2023-12-20	2025-06-26	Institut National De La Sante Et De La Recherche Medicale	Novel anti-tfr1 (cd71) antibodies for cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3788058T2 (de)	1986-08-28	1994-04-21	Teijin Ltd	Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
MD1367C2 (ro)	1992-11-13	2000-11-30	Idec Pharmaceuticals Corporation	Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP2535346B1 (en)	2005-08-31	2017-08-02	The Regents of The University of California	Cellular libraries of peptide sequences (CLiPS) and methods of using the same
CA2697032C (en)	2007-08-22	2021-09-14	The Regents Of The University Of California	Activatable binding polypeptides and methods of identification and use thereof
NZ599777A (en) *	2007-11-07	2013-09-27	Celldex Therapeutics Inc	Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US20100189651A1 (en)	2009-01-12	2010-07-29	Cytomx Therapeutics, Llc	Modified antibody compositions, methods of making and using thereof
US8765916B2 (en) *	2009-04-29	2014-07-01	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	ERG monoclonal antibodies
US9309325B2 (en)	2009-05-07	2016-04-12	The Regents Of The University Of California	Antibodies and methods of use thereof
WO2012104344A1 (en) *	2011-02-01	2012-08-09	Genmab A/S	Human antibodies and antibody-drug conjugates against cd74
EP3431504B1 (en) *	2012-01-31	2021-03-24	SBI Biotech Co., Ltd.	Anti-phospholipase d4 antibody
US9309510B2 (en)	2012-08-10	2016-04-12	Cytomx Therapeutics, Inc.	Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) *	2013-02-05	2014-05-21	浙江大学	一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
BR112017023862A2 (pt)	2015-05-04	2018-07-17	Cytomx Therapeutics Inc	anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
CN106237341B (zh) *	2016-07-12	2019-07-30	浙江大学	一种抗体偶联药物及其制备方法和应用
RU2771292C2 (ru) *	2017-10-14	2022-04-29	Эббви Инк.	Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения

2018
- 2018-10-12 RU RU2020115713A patent/RU2771292C2/ru active
- 2018-10-12 DK DK18797311.0T patent/DK3691692T3/da active
- 2018-10-12 LT LTEP18797311.0T patent/LT3691692T/lt unknown
- 2018-10-12 CA CA3077730A patent/CA3077730A1/en active Pending
- 2018-10-12 PH PH1/2020/550417A patent/PH12020550417A1/en unknown
- 2018-10-12 TW TW111137633A patent/TW202330039A/zh unknown
- 2018-10-12 PL PL18797311T patent/PL3691692T3/pl unknown
- 2018-10-12 RS RS20210341A patent/RS61596B1/sr unknown
- 2018-10-12 AU AU2018346969A patent/AU2018346969A1/en not_active Abandoned
- 2018-10-12 MX MX2020003723A patent/MX2020003723A/es unknown
- 2018-10-12 KR KR1020207013706A patent/KR102385495B1/ko not_active Expired - Fee Related
- 2018-10-12 AR ARP180102966A patent/AR115178A1/es not_active Application Discontinuation
- 2018-10-12 BR BR112020007302-4A patent/BR112020007302B1/pt active IP Right Grant
- 2018-10-12 MD MDE20200822T patent/MD3691692T2/ro unknown
- 2018-10-12 KR KR1020227011264A patent/KR20220045088A/ko not_active Ceased
- 2018-10-12 RU RU2022111211A patent/RU2022111211A/ru unknown
- 2018-10-12 PT PT187973110T patent/PT3691692T/pt unknown
- 2018-10-12 SM SM20210184T patent/SMT202100184T1/it unknown
- 2018-10-12 UY UY0001037931A patent/UY37931A/es not_active Application Discontinuation
- 2018-10-12 CR CR20200206A patent/CR20200206A/es unknown
- 2018-10-12 HU HUE18797311A patent/HUE054037T2/hu unknown
- 2018-10-12 US US16/159,559 patent/US20190111150A1/en not_active Abandoned
- 2018-10-12 KR KR1020237014403A patent/KR20230070046A/ko not_active Withdrawn
- 2018-10-12 EP EP18797311.0A patent/EP3691692B8/en active Active
- 2018-10-12 CN CN201880069577.4A patent/CN111278467B/zh active Active
- 2018-10-12 JP JP2020520804A patent/JP7374891B2/ja active Active
- 2018-10-12 PE PE2020000380A patent/PE20210125A1/es unknown
- 2018-10-12 MA MA50752A patent/MA50752B1/fr unknown
- 2018-10-12 SG SG11202003378WA patent/SG11202003378WA/en unknown
- 2018-10-12 ES ES18797311T patent/ES2864013T3/es active Active
- 2018-10-12 EP EP20209320.9A patent/EP3834846A1/en not_active Withdrawn
- 2018-10-12 WO PCT/US2018/055733 patent/WO2019075417A1/en not_active Ceased
- 2018-10-12 TW TW107136020A patent/TWI780237B/zh not_active IP Right Cessation
- 2018-10-12 KR KR1020227044475A patent/KR102529359B1/ko active Active
- 2018-10-12 SI SI201830233T patent/SI3691692T1/sl unknown
- 2018-10-12 HR HRP20210436TT patent/HRP20210436T8/hr unknown
2020
- 2020-03-25 IL IL273586A patent/IL273586A/en unknown
- 2020-04-09 CL CL2020000977A patent/CL2020000977A1/es unknown
- 2020-05-07 CO CONC2020/0005685A patent/CO2020005685A2/es unknown
- 2020-05-13 EC ECSENADI202025198A patent/ECSP20025198A/es unknown
- 2020-11-25 US US17/105,402 patent/US20210145978A1/en not_active Abandoned
2021
- 2021-03-22 CY CY20211100239T patent/CY1123968T1/el unknown
2023
- 2023-05-19 US US18/320,869 patent/US20240115724A1/en not_active Abandoned
- 2023-07-27 DO DO2023000150A patent/DOP2023000150A/es unknown
- 2023-10-25 JP JP2023183034A patent/JP2024012366A/ja active Pending

Also Published As

Publication number	Publication date
MD3691692T2 (ro)	2021-05-31
DK3691692T3 (da)	2021-03-22
PE20210125A1 (es)	2021-01-19
PT3691692T (pt)	2021-03-29
WO2019075417A1 (en)	2019-04-18
EP3691692A1 (en)	2020-08-12
IL273586A (en)	2020-05-31
ECSP20025198A (es)	2020-06-30
EP3834846A1 (en)	2021-06-16
PH12020550417A1 (en)	2021-04-12
KR102529359B1 (ko)	2023-05-09
ES2864013T3 (es)	2021-10-13
MA50752B1 (fr)	2021-03-31
CN111278467B (zh)	2024-07-30
CO2020005685A2 (es)	2020-05-15
SG11202003378WA (en)	2020-05-28
DOP2023000150A (es)	2023-08-31
BR112020007302B1 (pt)	2023-01-31
CN111278467A (zh)	2020-06-12
LT3691692T (lt)	2021-05-10
KR20230004932A (ko)	2023-01-06
EP3691692B8 (en)	2021-05-26
RU2022111211A (ru)	2022-05-05
EP3691692B1 (en)	2020-12-30
KR20220045088A (ko)	2022-04-12
CA3077730A1 (en)	2019-04-18
RU2771292C2 (ru)	2022-04-29
TW202330039A (zh)	2023-08-01
JP2020537649A (ja)	2020-12-24
HUE054037T2 (hu)	2021-08-30
US20190111150A1 (en)	2019-04-18
KR20230070046A (ko)	2023-05-19
US20240115724A1 (en)	2024-04-11
SI3691692T1 (sl)	2021-04-30
KR20200070324A (ko)	2020-06-17
TWI780237B (zh)	2022-10-11
TW201927815A (zh)	2019-07-16
US20210145978A1 (en)	2021-05-20
JP2024012366A (ja)	2024-01-30
CR20200206A (es)	2021-02-18
AR115178A1 (es)	2020-12-09
BR112020007302A2 (pt)	2020-09-29
SMT202100184T1 (it)	2021-05-07
AU2018346969A1 (en)	2020-04-23
JP7374891B2 (ja)	2023-11-07
RU2020115713A3 (pl)	2022-02-25
UY37931A (es)	2019-04-30
HRP20210436T8 (hr)	2022-01-07
RS61596B1 (sr)	2021-04-29
KR102385495B1 (ko)	2022-04-15
HRP20210436T1 (hr)	2021-04-30
MA50752A (fr)	2020-08-12
RU2020115713A (ru)	2021-11-16
CY1123968T1 (el)	2022-05-27
MX2020003723A (es)	2020-07-22
CL2020000977A1 (es)	2020-09-11

Publication	Publication Date	Title
IL273586A (en)	2020-05-31	Activatable anti-cd71 antibody-drug conjugates and methods of using them
IL272703A (en)	2020-04-30	Activatable anti-CD166 antibodies and methods of using them
IL270921A (en)	2020-01-30	Activatable anti-PDL1 antibodies and methods of using them
IL304717A (en)	2023-09-01	Antibody conjugates against cmet with drug and methods of using them
ZA201801401B (en)	2019-08-28	Anti-dll3 antibody drug conjugates and methods of use
ZA201900059B (en)	2022-11-30	Anti-b7-h3 antibodies and antibody drug conjugates
IL282856A (en)	2021-06-30	Activatable anti-CD166 antibodies and methods of using them
ZA201801957B (en)	2020-07-29	Pyrrolobenzodiazepine antibody drug conjugates and methods of use
IL265625A (en)	2019-05-30	Antibodies activated against ctla-4 and their uses
EP3572428A4 (en)	2020-12-30	ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
SG10201913762QA (en)	2020-03-30	Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
SG11201607746QA (en)	2016-10-28	Anti-egfr antibodies and antibody drug conjugates
EP3625253A4 (en)	2021-03-24	ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
EP3294810A4 (en)	2019-01-02	Silicon based drug conjugates and methods of using same
IL278225A (en)	2020-11-30	Anti SEZ6 antibody drug conjugates and methods of use
IL272920A (en)	2020-04-30	EGFR Antibody Drug Conjugates (ADC) and Their Uses
IL273048A (en)	2020-04-30	Melanin antibodies and their uses
HK40033435A (en)	2021-04-09	Activatable anti-cd166 antibodies and methods of use thereof
HK40004553A (en)	2020-04-29	Napi2b-targeted antibody-drug conjugates and methods of use thereof